Arno Therapeutics, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2015. For the quarter, the company reported loss from operations of $2,875,000 compared to $5,675,000 a year ago. Net loss was $679,000 or loss of $0.03 per diluted share compared to net loss of $159,000 or $0.01 per diluted share a year ago. Non-GAAP adjusted net loss was $1,944,000 or loss of $0.10 per basic share compared to $4,552,000 or $0.22 per basic share a year ago.

For the nine months, the company reported loss from operations of $10,716,000 compared to $17,603,000 a year ago. Net loss was $7,513,000 or loss of $0.37 per diluted share compared to net income of $3,208,000 or $0.13 per diluted share a year ago. Non-GAAP adjusted net loss was $7,842,000 or loss of $0.38 per basic share compared to $14,068,000 or $0.69 per basic share a year ago.